Komodo Health
1 2 3 4 5 6 7 8 9 10
CONTACT
1 2 3 4 5 6 7 8 9 10
CONTACT
WHY IT MATTERS
  • A lack of racial and ethnic representation in trials impedes researchers’ ability to capture differences in drug metabolism, efficacy, and side effects among subgroups
  • Pharma must follow the FDA’s race and ethnicity (R&E) diversity guidance
CHALLENGE #5
Clinical Trial Diversity
05_ClinicalTrialDiversity_Heads_v5-FlipH_1x_NoLoop

More than 50% of Clinical Development teams report it is a "significant to very significant challenge" to identify patients within racial and/or ethnic minority populations and the HCPs who are treating them.

What’s behind the challenge? 

  • Lack of demographic insights that mirror population and subpopulation composition at the national, regional, and state levels
  • Reliance on legacy inclusion/exclusion criteria that unnecessarily excludes certain populations
  • Lack of visibility into trial sites (e.g., in community settings) that could drive patient diversity
WHY IT MATTERS RESOLVE THIS CHALLENGE
05_ClinicalTrialDiversity_Heads_v5-FlipH_1x_NoLoop